Silver Book reference

Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis

1 Matching Fact

Search matching Facts:
No results to display
    • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.